nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—ADRB2—polycystic ovary syndrome	0.752	1	CbGaD
Salbutamol—Emotional distress—Metformin—polycystic ovary syndrome	0.00582	0.0551	CcSEcCtD
Salbutamol—Abdominal bloating—Metformin—polycystic ovary syndrome	0.00519	0.0492	CcSEcCtD
Salbutamol—Appetite absent—Metformin—polycystic ovary syndrome	0.00497	0.0471	CcSEcCtD
Salbutamol—Gastrointestinal symptom NOS—Metformin—polycystic ovary syndrome	0.00421	0.0398	CcSEcCtD
Salbutamol—Heartburn—Metformin—polycystic ovary syndrome	0.00359	0.034	CcSEcCtD
Salbutamol—Rigors—Metformin—polycystic ovary syndrome	0.00303	0.0287	CcSEcCtD
Salbutamol—Chest discomfort—Metformin—polycystic ovary syndrome	0.0028	0.0265	CcSEcCtD
Salbutamol—Accidental injury—Metformin—polycystic ovary syndrome	0.0028	0.0265	CcSEcCtD
Salbutamol—Lightheadedness—Metformin—polycystic ovary syndrome	0.00221	0.021	CcSEcCtD
Salbutamol—Ear pain—Metformin—polycystic ovary syndrome	0.0021	0.0199	CcSEcCtD
Salbutamol—Nasal congestion—Metformin—polycystic ovary syndrome	0.00197	0.0187	CcSEcCtD
Salbutamol—Injury—Metformin—polycystic ovary syndrome	0.00195	0.0185	CcSEcCtD
Salbutamol—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00184	0.0174	CcSEcCtD
Salbutamol—Migraine—Metformin—polycystic ovary syndrome	0.00177	0.0167	CcSEcCtD
Salbutamol—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00164	0.0155	CcSEcCtD
Salbutamol—Cramp muscle—Metformin—polycystic ovary syndrome	0.00162	0.0153	CcSEcCtD
Salbutamol—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00161	0.0152	CcSEcCtD
Salbutamol—Abdominal distension—Metformin—polycystic ovary syndrome	0.00156	0.0148	CcSEcCtD
Salbutamol—Influenza—Metformin—polycystic ovary syndrome	0.00155	0.0147	CcSEcCtD
Salbutamol—Angina pectoris—Metformin—polycystic ovary syndrome	0.00151	0.0143	CcSEcCtD
Salbutamol—Sweating increased—Metformin—polycystic ovary syndrome	0.00151	0.0143	CcSEcCtD
Salbutamol—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00144	0.0137	CcSEcCtD
Salbutamol—Drowsiness—Metformin—polycystic ovary syndrome	0.00138	0.0131	CcSEcCtD
Salbutamol—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00136	0.0128	CcSEcCtD
Salbutamol—Rhinitis—Metformin—polycystic ovary syndrome	0.00125	0.0118	CcSEcCtD
Salbutamol—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00124	0.0117	CcSEcCtD
Salbutamol—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00122	0.0116	CcSEcCtD
Salbutamol—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00115	0.0109	CcSEcCtD
Salbutamol—Flushing—Metformin—polycystic ovary syndrome	0.00115	0.0109	CcSEcCtD
Salbutamol—Angiopathy—Metformin—polycystic ovary syndrome	0.00113	0.0107	CcSEcCtD
Salbutamol—Immune system disorder—Metformin—polycystic ovary syndrome	0.00112	0.0106	CcSEcCtD
Salbutamol—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00112	0.0106	CcSEcCtD
Salbutamol—Chills—Metformin—polycystic ovary syndrome	0.00111	0.0106	CcSEcCtD
Salbutamol—Malnutrition—Metformin—polycystic ovary syndrome	0.00108	0.0102	CcSEcCtD
Salbutamol—Flatulence—Metformin—polycystic ovary syndrome	0.00107	0.0101	CcSEcCtD
Salbutamol—Dysgeusia—Metformin—polycystic ovary syndrome	0.00106	0.01	CcSEcCtD
Salbutamol—Muscle spasms—Metformin—polycystic ovary syndrome	0.00104	0.00984	CcSEcCtD
Salbutamol—Tremor—Metformin—polycystic ovary syndrome	0.00101	0.00959	CcSEcCtD
Salbutamol—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.001	0.0095	CcSEcCtD
Salbutamol—Malaise—Metformin—polycystic ovary syndrome	0.000975	0.00923	CcSEcCtD
Salbutamol—Syncope—Metformin—polycystic ovary syndrome	0.00097	0.00918	CcSEcCtD
Salbutamol—Palpitations—Metformin—polycystic ovary syndrome	0.000955	0.00905	CcSEcCtD
Salbutamol—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00095	0.009	CcSEcCtD
Salbutamol—Hypertension—Metformin—polycystic ovary syndrome	0.000933	0.00884	CcSEcCtD
Salbutamol—Nadolol—ADRB3—polycystic ovary syndrome	0.00093	0.0701	CrCbGaD
Salbutamol—Myalgia—Metformin—polycystic ovary syndrome	0.000921	0.00872	CcSEcCtD
Salbutamol—Chest pain—Metformin—polycystic ovary syndrome	0.000921	0.00872	CcSEcCtD
Salbutamol—Discomfort—Metformin—polycystic ovary syndrome	0.000909	0.00861	CcSEcCtD
Salbutamol—Phenylephrine—ADRA1D—polycystic ovary syndrome	0.000904	0.0681	CrCbGaD
Salbutamol—Clenbuterol—ADRB3—polycystic ovary syndrome	0.000897	0.0676	CrCbGaD
Salbutamol—Bupranolol—ADRB3—polycystic ovary syndrome	0.000887	0.0669	CrCbGaD
Salbutamol—Oedema—Metformin—polycystic ovary syndrome	0.000882	0.00835	CcSEcCtD
Salbutamol—Infection—Metformin—polycystic ovary syndrome	0.000877	0.0083	CcSEcCtD
Salbutamol—Shock—Metformin—polycystic ovary syndrome	0.000868	0.00822	CcSEcCtD
Salbutamol—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000865	0.00819	CcSEcCtD
Salbutamol—Skin disorder—Metformin—polycystic ovary syndrome	0.000857	0.00812	CcSEcCtD
Salbutamol—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000853	0.00808	CcSEcCtD
Salbutamol—Anorexia—Metformin—polycystic ovary syndrome	0.000841	0.00796	CcSEcCtD
Salbutamol—Hypotension—Metformin—polycystic ovary syndrome	0.000825	0.00781	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000804	0.00761	CcSEcCtD
Salbutamol—Paraesthesia—Metformin—polycystic ovary syndrome	0.000792	0.0075	CcSEcCtD
Salbutamol—Dyspnoea—Metformin—polycystic ovary syndrome	0.000787	0.00745	CcSEcCtD
Salbutamol—Somnolence—Metformin—polycystic ovary syndrome	0.000784	0.00743	CcSEcCtD
Salbutamol—Dyspepsia—Metformin—polycystic ovary syndrome	0.000777	0.00735	CcSEcCtD
Salbutamol—Phenylephrine—ADRA1B—polycystic ovary syndrome	0.000771	0.0581	CrCbGaD
Salbutamol—Decreased appetite—Metformin—polycystic ovary syndrome	0.000767	0.00726	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000762	0.00721	CcSEcCtD
Salbutamol—Fatigue—Metformin—polycystic ovary syndrome	0.000761	0.0072	CcSEcCtD
Salbutamol—Constipation—Metformin—polycystic ovary syndrome	0.000755	0.00714	CcSEcCtD
Salbutamol—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000727	0.00688	CcSEcCtD
Salbutamol—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000722	0.00683	CcSEcCtD
Salbutamol—Urticaria—Metformin—polycystic ovary syndrome	0.000701	0.00664	CcSEcCtD
Salbutamol—Abdominal pain—Metformin—polycystic ovary syndrome	0.000698	0.0066	CcSEcCtD
Salbutamol—Asthenia—Metformin—polycystic ovary syndrome	0.000633	0.00599	CcSEcCtD
Salbutamol—Pruritus—Metformin—polycystic ovary syndrome	0.000624	0.00591	CcSEcCtD
Salbutamol—Diarrhoea—Metformin—polycystic ovary syndrome	0.000604	0.00572	CcSEcCtD
Salbutamol—Dizziness—Metformin—polycystic ovary syndrome	0.000584	0.00552	CcSEcCtD
Salbutamol—Vomiting—Metformin—polycystic ovary syndrome	0.000561	0.00531	CcSEcCtD
Salbutamol—Rash—Metformin—polycystic ovary syndrome	0.000556	0.00527	CcSEcCtD
Salbutamol—Dermatitis—Metformin—polycystic ovary syndrome	0.000556	0.00526	CcSEcCtD
Salbutamol—Headache—Metformin—polycystic ovary syndrome	0.000553	0.00523	CcSEcCtD
Salbutamol—Nausea—Metformin—polycystic ovary syndrome	0.000524	0.00496	CcSEcCtD
Salbutamol—Pirbuterol—ADRB2—polycystic ovary syndrome	0.000524	0.0395	CrCbGaD
Salbutamol—Phenylephrine—ADRA1A—polycystic ovary syndrome	0.000519	0.0391	CrCbGaD
Salbutamol—Levobunolol—ADRB2—polycystic ovary syndrome	0.000467	0.0352	CrCbGaD
Salbutamol—Norepinephrine—ADRA1D—polycystic ovary syndrome	0.000463	0.0349	CrCbGaD
Salbutamol—Isoprenaline—ADRB3—polycystic ovary syndrome	0.000449	0.0338	CrCbGaD
Salbutamol—Levonordefrin—ADRA1A—polycystic ovary syndrome	0.000448	0.0338	CrCbGaD
Salbutamol—Terbutaline—ADRB2—polycystic ovary syndrome	0.000427	0.0322	CrCbGaD
Salbutamol—Epinephrine—ADRA1D—polycystic ovary syndrome	0.00042	0.0316	CrCbGaD
Salbutamol—Norepinephrine—ADRB3—polycystic ovary syndrome	0.000415	0.0313	CrCbGaD
Salbutamol—Isoetarine—ADRB2—polycystic ovary syndrome	0.000411	0.031	CrCbGaD
Salbutamol—Carteolol—ADRB2—polycystic ovary syndrome	0.000397	0.0299	CrCbGaD
Salbutamol—Norepinephrine—ADRA1B—polycystic ovary syndrome	0.000395	0.0297	CrCbGaD
Salbutamol—Epinephrine—ADRB3—polycystic ovary syndrome	0.000377	0.0284	CrCbGaD
Salbutamol—Salmeterol—ADRB2—polycystic ovary syndrome	0.000363	0.0273	CrCbGaD
Salbutamol—Epinephrine—ADRA1B—polycystic ovary syndrome	0.000358	0.027	CrCbGaD
Salbutamol—Nadolol—ADRB2—polycystic ovary syndrome	0.000354	0.0267	CrCbGaD
Salbutamol—Clenbuterol—ADRB2—polycystic ovary syndrome	0.000341	0.0257	CrCbGaD
Salbutamol—Bupranolol—ADRB2—polycystic ovary syndrome	0.000337	0.0254	CrCbGaD
Salbutamol—Clenbuterol—CYP1A1—polycystic ovary syndrome	0.000293	0.0221	CrCbGaD
Salbutamol—Norepinephrine—ADRA1A—polycystic ovary syndrome	0.000266	0.02	CrCbGaD
Salbutamol—Epinephrine—ADRA1A—polycystic ovary syndrome	0.000241	0.0182	CrCbGaD
Salbutamol—Isoprenaline—ADRB2—polycystic ovary syndrome	0.000171	0.0129	CrCbGaD
Salbutamol—ADRB2—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00016	0.00124	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—NPB—polycystic ovary syndrome	0.000158	0.00122	CbGpPWpGaD
Salbutamol—Norepinephrine—ADRB2—polycystic ovary syndrome	0.000158	0.0119	CrCbGaD
Salbutamol—ADRB1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.000158	0.00122	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.000158	0.00122	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.000157	0.00122	CbGpPWpGaD
Salbutamol—ADRB1—G alpha (s) signalling events—POMC—polycystic ovary syndrome	0.000157	0.00121	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.000157	0.00121	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.000154	0.00119	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.000154	0.00119	CbGpPWpGaD
Salbutamol—ADRB2—G alpha (s) signalling events—POMC—polycystic ovary syndrome	0.000154	0.00119	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.000154	0.00119	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—SCT—polycystic ovary syndrome	0.000153	0.00118	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.00015	0.00116	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00015	0.00116	CbGpPWpGaD
Salbutamol—CYP3A4—Tryptophan metabolism—CYP1A1—polycystic ovary syndrome	0.000149	0.00115	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.000149	0.00115	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.000149	0.00115	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.000148	0.00114	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.000146	0.00113	CbGpPWpGaD
Salbutamol—Isoprenaline—CYP1A1—polycystic ovary syndrome	0.000146	0.011	CrCbGaD
Salbutamol—ADRB1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.000146	0.00113	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.000145	0.00112	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.000145	0.00112	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.000145	0.00112	CbGpPWpGaD
Salbutamol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.000144	0.00111	CbGpPWpGaD
Salbutamol—Epinephrine—ADRB2—polycystic ovary syndrome	0.000143	0.0108	CrCbGaD
Salbutamol—ADRB2—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.000143	0.0011	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.000142	0.0011	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00014	0.00108	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.000139	0.00107	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.000136	0.00105	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.000135	0.00104	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.000135	0.00104	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.000135	0.00104	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.000132	0.00102	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.000132	0.00102	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.000132	0.00102	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.000131	0.00101	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.000128	0.000991	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.000126	0.000974	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.000123	0.000953	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.000123	0.000946	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000121	0.000938	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000121	0.000933	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00012	0.000928	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00012	0.000925	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.000119	0.000922	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000119	0.000921	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.000119	0.00092	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.000117	0.000902	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.000117	0.0009	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.000111	0.000853	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000109	0.000844	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.000109	0.00084	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.000108	0.000837	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.000108	0.000835	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000107	0.000825	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.000106	0.000821	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000106	0.000819	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.000106	0.000819	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	9.95e-05	0.000768	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	9.9e-05	0.000765	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—FSHR—polycystic ovary syndrome	9.88e-05	0.000763	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	9.79e-05	0.000756	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	9.77e-05	0.000754	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	9.73e-05	0.000751	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—FSHR—polycystic ovary syndrome	9.66e-05	0.000746	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	9.57e-05	0.000739	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NPB—polycystic ovary syndrome	9.55e-05	0.000737	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—LHB—polycystic ovary syndrome	9.46e-05	0.000731	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	9.37e-05	0.000723	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NPB—polycystic ovary syndrome	9.34e-05	0.000721	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—LHB—polycystic ovary syndrome	9.25e-05	0.000715	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	9.25e-05	0.000714	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	9.15e-05	0.000706	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	9.05e-05	0.000698	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	9.03e-05	0.000697	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	9.01e-05	0.000695	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—SCT—polycystic ovary syndrome	8.87e-05	0.000685	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	8.84e-05	0.000682	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	8.77e-05	0.000677	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	8.69e-05	0.000671	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—SCT—polycystic ovary syndrome	8.67e-05	0.00067	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	8.65e-05	0.000668	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	8.64e-05	0.000667	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—LHB—polycystic ovary syndrome	8.59e-05	0.000663	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	8.5e-05	0.000657	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—GNAS—polycystic ovary syndrome	8.48e-05	0.000655	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	8.46e-05	0.000653	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	8.45e-05	0.000652	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—LHB—polycystic ovary syndrome	8.4e-05	0.000649	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	8.4e-05	0.000648	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—GNAS—polycystic ovary syndrome	8.3e-05	0.000641	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	8.27e-05	0.000639	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	8.21e-05	0.000634	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	8.17e-05	0.000631	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	8.15e-05	0.00063	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—SCT—polycystic ovary syndrome	8.05e-05	0.000622	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	8.04e-05	0.000621	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTGER3—polycystic ovary syndrome	7.97e-05	0.000615	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LHCGR—polycystic ovary syndrome	7.97e-05	0.000615	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—SCT—polycystic ovary syndrome	7.87e-05	0.000608	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTGER3—polycystic ovary syndrome	7.8e-05	0.000602	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LHCGR—polycystic ovary syndrome	7.8e-05	0.000602	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	7.68e-05	0.000593	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	7.51e-05	0.00058	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	7.5e-05	0.000579	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTAFR—polycystic ovary syndrome	7.46e-05	0.000576	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	7.34e-05	0.000567	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	7.3e-05	0.000564	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTAFR—polycystic ovary syndrome	7.29e-05	0.000563	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	7.24e-05	0.000559	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	7.08e-05	0.000547	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	7.04e-05	0.000544	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	6.89e-05	0.000532	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INHBB—polycystic ovary syndrome	6.86e-05	0.00053	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	6.71e-05	0.000518	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	6.45e-05	0.000498	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDE3B—polycystic ovary syndrome	6.41e-05	0.000495	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	6.36e-05	0.000491	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	6.27e-05	0.000484	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	6.25e-05	0.000482	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	6.11e-05	0.000472	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FSHR—polycystic ovary syndrome	5.83e-05	0.00045	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—POMC—polycystic ovary syndrome	5.71e-05	0.000441	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	5.71e-05	0.000441	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GHRL—polycystic ovary syndrome	5.67e-05	0.000438	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	5.59e-05	0.000431	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	5.55e-05	0.000428	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	5.48e-05	0.000424	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	5.37e-05	0.000414	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	5.34e-05	0.000412	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	5.22e-05	0.000403	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	5.2e-05	0.000402	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FST—polycystic ovary syndrome	5.2e-05	0.000402	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	5.17e-05	0.000399	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRB3—polycystic ovary syndrome	5.14e-05	0.000397	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	5.13e-05	0.000396	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	5.09e-05	0.000393	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LHB—polycystic ovary syndrome	5.08e-05	0.000392	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	5.02e-05	0.000388	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	4.96e-05	0.000383	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.96e-05	0.000383	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	4.85e-05	0.000375	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.8e-05	0.000371	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	4.79e-05	0.00037	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	4.76e-05	0.000367	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.7e-05	0.000363	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	4.69e-05	0.000363	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	4.69e-05	0.000362	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	4.65e-05	0.000359	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	4.58e-05	0.000353	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.54e-05	0.00035	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	4.46e-05	0.000344	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.44e-05	0.000343	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	4.42e-05	0.000341	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	4.36e-05	0.000337	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	4.35e-05	0.000336	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	4.32e-05	0.000334	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	4.26e-05	0.000329	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	4.18e-05	0.000323	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	4.18e-05	0.000323	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	4.13e-05	0.000319	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	4.07e-05	0.000314	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	4.04e-05	0.000312	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	3.98e-05	0.000307	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	3.89e-05	0.000301	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	3.89e-05	0.0003	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	3.88e-05	0.000299	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	3.81e-05	0.000294	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.7e-05	0.000286	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.64e-05	0.000281	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.62e-05	0.000279	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	3.6e-05	0.000278	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.56e-05	0.000275	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	3.53e-05	0.000272	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	3.35e-05	0.000259	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	3.35e-05	0.000259	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	3.31e-05	0.000255	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	3.31e-05	0.000255	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	3.28e-05	0.000253	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	3.28e-05	0.000253	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	3.23e-05	0.000249	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	3.2e-05	0.000247	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	3.16e-05	0.000244	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	3.13e-05	0.000241	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	3.12e-05	0.000241	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	3.1e-05	0.00024	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	3.05e-05	0.000235	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	3.04e-05	0.000234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	2.95e-05	0.000228	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	2.93e-05	0.000226	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	2.92e-05	0.000226	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	2.89e-05	0.000223	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	2.87e-05	0.000221	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	2.86e-05	0.000221	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.82e-05	0.000218	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.77e-05	0.000214	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	2.77e-05	0.000214	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.76e-05	0.000213	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	2.63e-05	0.000203	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	2.57e-05	0.000199	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	2.52e-05	0.000194	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	2.51e-05	0.000194	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.45e-05	0.000189	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	2.4e-05	0.000186	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.4e-05	0.000185	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	2.35e-05	0.000182	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	2.23e-05	0.000173	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	2.13e-05	0.000165	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	2.06e-05	0.000159	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	2.02e-05	0.000156	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.01e-05	0.000156	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	1.97e-05	0.000152	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.94e-05	0.00015	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.9e-05	0.000147	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.84e-05	0.000142	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.8e-05	0.000139	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.76e-05	0.000136	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	1.73e-05	0.000134	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	1.72e-05	0.000133	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	1.69e-05	0.000131	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.69e-05	0.000131	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	1.68e-05	0.00013	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.67e-05	0.000129	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.66e-05	0.000129	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.64e-05	0.000127	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.63e-05	0.000126	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.63e-05	0.000126	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.58e-05	0.000122	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.58e-05	0.000122	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.55e-05	0.000119	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.52e-05	0.000117	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.5e-05	0.000116	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.42e-05	0.000109	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.39e-05	0.000108	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.27e-05	9.84e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.25e-05	9.62e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.21e-05	9.32e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.17e-05	9.06e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.1e-05	8.52e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.09e-05	8.4e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.06e-05	8.22e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	9.85e-06	7.61e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	9.38e-06	7.25e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	8.9e-06	6.87e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	8.29e-06	6.4e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	7.52e-06	5.81e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	7.36e-06	5.68e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	6.73e-06	5.19e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	6.63e-06	5.12e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—INS—polycystic ovary syndrome	6.6e-06	5.09e-05	CbGpPWpGaD
